A phase 1 dose-escalation study: Safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

Haematologica

Volumn 96, Issue 4, 2011, Pages 521-525

  Rienhoff, Hugh Young ^a   Viprakasit, Vip ^b   Tay, Lay ^c   Harmatz, Paul ^d   Vichinsky, Elliott ^d   Chirnomas, Deborah ^e   Kwiatkowski, Janet L ^f   Tapper, Amy ^a   Kramer, William ^a   Porter, John B ^g   Neufeld, Ellis J ^e  

^a FerroKin BioSciences   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dose escalation; Fbs0701; Oral iron chelator; Phase I study

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FBS 0701; IRON; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

ABDOMINAL WARMTH; ADULT; ALPHA THALASSEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; COHORT ANALYSIS; CONGENITAL DYSERYTHROPOIETIC ANEMIA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON OVERLOAD; IRON URINE LEVEL; ISCHIALGIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRURITUS; SICKLE CELL ANEMIA; SIDE EFFECT; STEADY STATE; STOMACH PAIN; THALASSEMIA MAJOR; TREATMENT DURATION; URINE COLOR;

ADMINISTRATION, ORAL; ADULT; BLOOD TRANSFUSION; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; YOUNG ADULT;

EID: 79953853812     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.034405     Document Type: Article

References (8)

1. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9):3436-3441.
2. Naegeli H-U, Zähner H. Stoffwechsel -produkte von Mikroorganismen. 193. Mitteilung. Ferrithiocin. Helvetica Chimica Acta. 1980;63(6):1400-1406.
3. Hahn FE, McMurry TJ, Hugi A, Raymond KN. Coordination chemistry of microbial iron transport. 42. Structural and spectro- scopic characterization of diastereomeric chromium(III) and cobalt(III) complexes of desferrithiocin. J Am Chem. Soc. 1990;112: 1854-1860.
4. Anderegg G, Raeber M. Metal complex formation of a new siderophore desferrithiocin and of three related ligands. J Chem Soc, Chem Commun. 1990;17: 1194-1196.
5. Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem. 2008; 51(13):3913-3923.
6. ® (deferasirox) European Public Assessment Report. http://www. emea.europa.eu/humandocs/Humans/EPAR /exjade/exjade.htm.
7. Galanello R, Piga A, Alberti D, Rouan M, Bigler H, Sechad R. Safety, tolerability and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to b-thalassemia. J Clin Pharmacol. 2003;43 (6):565-572.
8. Liem R, Young L, Thompson A. Prolonged QTc interval in children and young adults with sickle cell disease at steady state. Pediatr Blood Cancer. 2009;52(7): 842-846.